Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company advancing targeted therapies for endocrine-driven breast cancers. This page provides investors and healthcare professionals with timely updates on clinical developments, financial disclosures, and strategic initiatives.
Access consolidated information about OLMA's lead candidate palazestrant (OP-1250), an oral complete estrogen receptor antagonist/SERD, and other pipeline assets like the KAT6 inhibitor OP-3136. Track regulatory milestones, partnership announcements, and peer-reviewed research findings in one centralized location.
Key updates include clinical trial progress, scientific conference presentations, and financial results. All content is sourced from official company communications and verified industry reports to ensure accuracy.
Bookmark this page for streamlined access to OLMA's latest developments in women's oncology therapeutics. Check regularly for essential updates impacting treatment innovation and corporate strategy.
Olema Oncology (Nasdaq: OLMA) has announced upcoming presentation of preclinical data for OP-3136, their novel KAT6 inhibitor, at the 2025 AACR Annual Meeting in Chicago. The presentation will showcase the drug's anti-tumor activity in multiple solid tumor models, including prostate, ovarian, and non-small cell lung cancer.
The research demonstrates that OP-3136 functions as a potent and selective inhibitor of lysine acetyltransferase 6 (KAT6). Dr. Gopinath S. Palanisamy will present these findings in a late-breaking poster session (LB166) on April 28, 2025, from 9:00am-12:00pm CT.
Olema Oncology (NASDAQ: OLMA) reported its Q4 and full year 2024 financial results, highlighting significant progress in its breast cancer treatment pipeline. The company ended 2024 with $434.1 million in cash and equivalents, bolstered by a $250 million equity private placement.
Key developments include the advancement of two pivotal Phase 3 trials: OPERA-01 for palazestrant monotherapy in metastatic breast cancer (top-line data expected 2026) and OPERA-02 for palazestrant with ribociclib in frontline treatment, supported by a new Novartis collaboration.
Financial results showed a net loss of $33.6 million for Q4 and $129.5 million for full-year 2024, compared to $26.8 million and $96.7 million in 2023, respectively. R&D expenses increased to $124.5 million for 2024, up from $86.1 million in 2023, reflecting expanded clinical development activities.
Olema Pharmaceuticals (Nasdaq: OLMA) has announced new employee stock option grants. Two new employees received a total of 19,800 stock options at $4.21 per share, effective March 3, 2025. Additionally, newly appointed Chief Legal Officer and Corporate Secretary Shawnte Mitchell received 450,000 stock options at $4.37 per share, effective February 28, 2025.
All grants were made under Olema's 2022 Inducement Plan and approved by the Compensation Committee. The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting in 36 monthly installments, subject to continued employment. The options have a 10-year term.
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its upcoming participation at the TD Cowen 45th Annual Health Care Conference.
The company's President and Chief Executive Officer, Sean P. Bohen, M.D., Ph.D., will deliver a presentation on March 5, 2025, at 10:30 a.m. ET.
Investors and interested parties can access a live webcast of the presentation and related materials through the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording will also be made available at the same location following the presentation.
Olema Pharmaceuticals (Nasdaq: OLMA) has appointed Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary. Mitchell brings 20 years of experience in healthcare, life sciences, and sustainability industries. She previously served as Chief Legal Officer at Genomatica and held executive positions at Zogenix and Aptevo Therapeutics.
Mitchell will lead Olema's Legal function as the company advances its late-stage palazestrant programs and OP-3136 KAT6 program through clinical development. Her expertise spans regulatory, commercial, intellectual property, and business development matters. Mitchell holds a B.S. in Biological Sciences from Stanford University and a J.D. from The George Washington University Law School.
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has announced new stock option grants to six employees. The grants, approved by the Compensation Committee under the company's 2022 Inducement Plan, total 285,000 shares with an exercise price of $5.96 per share.
The stock options feature a four-year vesting schedule, with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments over the following three years. The options have a 10-year term and are contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for new employees joining the company.
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in two upcoming investor conferences in February 2025.
The company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 9:20 a.m. ET through a virtual presentation. Additionally, Olema will participate in Citi's 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025, at 10 a.m. ET in a virtual fireside chat format.
Live webcasts of both presentations will be accessible through the Events and Presentations section of Olema's investor relations website at ir.olema.com, with recordings available for at least 30 days after the events.
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to three new employees. The grants, approved by the Compensation Committee and issued under the company's 2022 Inducement Plan, allow the purchase of 26,200 shares of common stock at $5.57 per share.
The options, effective January 2, 2025, have a 10-year term and vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments over the following three years, contingent on continuous employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for new employment.
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Sean P. Bohen, M.D., President and Chief Executive Officer, will deliver a presentation on Tuesday, January 14, 2025, at 3:45 p.m. PT (6:45 p.m. ET) in San Francisco, California.
The presentation will be accessible via live webcast, along with any accompanying materials, through the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording will also be made available at the same location following the presentation.
Olema Oncology announced updated clinical results for palazestrant combined with ribociclib in treating ER+/HER2- advanced or metastatic breast cancer. With a 12-month median follow-up, the study showed promising results with median progression-free survival (PFS) not yet reached. The 6-month PFS rate was 73% overall, with 81% in ESR1 mutation patients and 70% in ESR1 wild-type patients.
The Phase 1b/2 study included 62 patients, with 56 receiving the recommended Phase 2 dose. The combination demonstrated favorable tolerability and safety profile consistent with ribociclib and endocrine therapy. Notable outcomes include a 76% clinical benefit rate across all patients and 27% objective response rate in patients with measurable disease.
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
